Skip to main content

Table 4 Univariate and multivariate Cox proportional hazards analyses of risk factors for death in patients with MDA5+DM

From: Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody

Variable

Univariate

Multivariate

HR (95% CI)

P-value

HR (95% CI)

P-value

Sex, female

0.45 (0.22–0.90)

0.024

0.75 (0.31–1.78)

0.512

Age > 57 years old

4.45 (2.17–9.15)

< 0.001

3.05 (1.20–7.80)

0.020

Ferritin > 1002.6 ng/mL

3.54 (1.60–7.82)

0.002

0.89 (0.29–2.76)

0.837

LDH > 388 U/L

2.92 (1.46–5.85)

0.002

1.29 (0.39–4.22)

0.674

ESR > 63 mm/h

3.54 (1.72–7.28)

0.001

1.78 (0.73–4.38)

0.208

Total lymphocyte count (/µL)

1.00 (1.00–1.00)

0.071

CD3+T lymphocyte count (/µL)

1.00 (1.00–1.00)

0.021

1.00 (1.00–1.00)

0.828

CD8+T lymphocyte count (/µL)

1.00 (0.99–1.00)

0.023

1.00 (0.99–1.01)

0.978

Levels of anti-MDA5 antibody

1.43 (0.75–2.71)

0.277

Levels of anti-Ro52 antibody

1.70 (1.26–2.31)

0.001

3.41 (1.36–8.53)

0.009

RP-ILD

37.73 (11.34–125.6)

< 0.001

25.07 (5.42–115.98)

< 0.001

  1. Bold text highlights the significance
  2. “–” indicates not included in the multivariate model due to the lack of significant association in univariate analysis
  3. MDA5+DM Anti-MDA5 dermatomyositis, LDH Lactate dehydrogenase, ESR Erythrocyte sedimentation rate, RP-ILD Rapidly progressive interstitial lung disease